Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-blockers for arrhythmia prevention after PFO closure
NCT07123506Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2025
- Primary completion
- Nov 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of bisoprolol and nebivolol in Supraventricular arrhythmia (SVA) (2 arms), sponsored by Yonsei University. Primary endpoint: Incidence of symptomatic or asymptomatic atrial fibrillation, atrial flutter, and atrial tachycardia at 30 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bisoprololnebivolol
03
Conditions
Supraventricular arrhythmia (SVA)
Beyond the preview
Go deeper on NCT07123506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123506.